The pharmaceutical company Solopharm has reported sustainable growth in industrial production across Russia, particularly in St. Petersburg, creating favorable conditions for the further development of the pharmaceutical sector and expansion of the company’s manufacturing capacities.
According to regional authorities, the industrial production index in St. Petersburg for January–February 2026 increased by 7.1% compared to the same period last year. This growth significantly outpaces the national average, where a decline in industrial output was recorded at the beginning of the year.
The pharmaceutical sector plays a particularly important role in this industrial growth: the production of medicines in St. Petersburg rose by 11.1%, with Solopharm being named among the industry leaders.
Further evidence of the company’s strong market position is its inclusion among the top pharmaceutical companies in Russia by the end of 2025, reflecting its contribution to the development of the industry and the growth of domestic drug production.
Comment from Solopharm Press Office:
«The growth in industrial and pharmaceutical production in Russia confirms the effectiveness of the strategy to develop local manufacturing. We remain focused on quality, innovation, and sustainable development, supporting both the healthcare system and patients».
